source
- AI monitoring tool could generate up to 82-fold ROI in phase-3 oncology trials, study findsAn analysis by the Tufts Center for the Study of Drug Development found that an artificial-intelligence clinical monitoring agent can produce an estimated 82-fold return on investment in phase-3 on…
- AbCellera, Silence and InduPro secure major funding rounds as AbCellera completes $200M share saleVancouver based biotech AbCellera announced a $200 million share offering after meeting its efficacy targets in a Phase 2 hot flashes trial. The capital raise follows the company achieving its pred…